![One of the major scientific crusades in oncology has been to identify and validate biomarkers associated with recurrent breast cancer. [iStock / royaltystockphoto]](https://www.clinicalomics.com/wp-content/uploads/2019/01/585-218x150.jpeg "Agendia Reports Positive Results in IMPACt Trial for Breast Cancer")
![Berg will partner with Massachusetts General Hospital and Brigham and Women's Hospital to study potential biomarkers for Alzheimer's and other neurodegenerative disorders from Harvard Biomarker Study biospecimens. [Source: ajcity.net]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1397-218x150.jpeg "Protein that Prevents Tau Clearance Linked to AD and Other Tau Tangle Proteinopathies")
10 Countries in 100K Genome Club
These ten governments have committed funding for projects that will sequence a minimum of 100,000 citizens to spur genomic medicine
8 Companion Diagnostic Developers Making a Mark
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
10 Liquid Biopsy Companies in the Money
10 privately-held diagnostics developers primarily focused on liquid biopsy tests, ranked by total money raised from venture capital firms.
UnitedHealthcare To Cover Genetic Testing for Precision Medicine in Depression, Anxiety
The nation’s largest private health insurer, UnitedHealthcare, announced August 1 that it will cover testing that will allow physicians to match their patients to...
Small Sequencer Developer GenapSys Completes $90M Series C Financing
GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
PerkinElmer Genomics, U. of Iowa Develop FSHD Assay Based on Bionano’s Saphyr
Bionano Genomics announced at the American Society of Human Genetics (ASHG) annual meeting in Houston that PerkinElmer Genomics and the University of Iowa have...
Promega to Develop MSI Technology as CDx to Merck’s Keytruda
Promega’s MSI testing is designed to functionally measure the genomic accumulation of insertion or deletion (INDEL) errors caused by a deficient mismatch-repair system (dMMR) that occurs in certain types of solid tumors.
Invitae Offers Free Genetic Testing for Four Conditions
Invitae said it is offering for free its Detect genetic testing programs for four conditions: Muscular dystrophy, hereditary prostate cancer, familial cardiomyopathy and arrhythmia,...
Clinical Urologists Group Supports Genomic Testing for Prostate Cancer
AACU statement encourages use of tissue-based molecular testing and/or germline testing for three groups of prostate cancer patients
Genomind Launching Enhanced Mental Health Biomarker Test
Genomind said today it will launch an enhanced version of its mental health genetic test that will feature a new, more focused report and...
